Ruxience

Showing 3 posts of 3 posts found.

Pfizer scores EU approval for MabThera biosimilar Ruxience

April 6, 2020
Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar

The European Commission has moved to authorise Ruxience, Pfizer’s biosimilar version of MabThera (rituximab).  The decision marks the seventh biosimilar …

Europe’s CHMP recommends Pfizer’s biosimilar of Roche’s MabThera

February 4, 2020
Manufacturing and Production, Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for …

fda2outsideweb

FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan

July 24, 2019
Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma

Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …

Latest content